Research programme: immuno-modulatory therapeutics - Bristol-Myers Squibb

Drug Profile

Research programme: immuno-modulatory therapeutics - Bristol-Myers Squibb

Alternative Names: NLRP3 agonists; STING agonists

Latest Information Update: 08 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator IFM therapeutics
  • Class Immunotherapies; Small molecules
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Autoimmune disorders; Inflammation; Solid tumours

Most Recent Events

  • 03 Aug 2017 Bristol-Myers Squibb acquires their immuno-modulatory therapeutics programme from IFM Therapeutics
  • 22 Jun 2016 Preclinical trials in Inflammation in USA
  • 22 Jun 2016 Preclinical trials in Solid tumours in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top